Streetbeat News

Equity Actions

MEG

Montrose Environmental Group has announced the pricing of its public offering of 3,000,000 shares at $37.15 each, causing its shares to trade higher.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 6:32 pm

KRRO

Korro Bio's stock is trading lower following the announcement of a $70 million private placement.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 6:26 pm

HD

Financial analysis reveals a bearish sentiment among traders on Home Depot (NYSE:HD) with 87% of options trades showing bearish tendencies. The analysis included 16 unusual trades, highlighting a significant interest in puts over calls. The projected price targets for HD range from $300.0 to $395.0. The largest trades observed indicate a mix of bearish and neutral sentiments, with significant open interest in options expiring in 2024. Home Depot's current stock price is slightly up, with analysts giving mixed ratings but leaning towards a positive outlook with an average target price of $385.0.

Portfolio Pulse from Benzinga Insights

April 18, 2024 | 6:18 pm

DNTH

Dianthus Therapeutics (NASDAQ:DNTH) has received varied analyst ratings over the past three months, with a recent shift towards more bullish sentiments. The average 12-month price target for DNTH has been raised to $38.2, a 48.35% increase from the previous target, indicating a positive outlook from analysts. Despite a significant decline in revenue growth and a high net margin indicating profitability challenges, the company's strong financial performance metrics like ROE and ROA, along with a sound debt management strategy, suggest a mixed financial health. The company focuses on developing complement therapeutics for autoimmune and inflammatory diseases.

Portfolio Pulse from Benzinga Insights

April 18, 2024 | 6:01 pm

MRK

17 analysts have recently provided ratings on Merck & Co (NYSE:MRK), showing a mix of bullish to bearish sentiments. The average 12-month price target is $135.35, indicating a 2.54% increase from the previous target of $132.00. Analyst actions include maintaining, raising, and announcing ratings with price targets ranging from $104.00 to $148.00. Merck's financial overview highlights a market capitalization above industry benchmarks, a 5.78% revenue growth over 3 months, but challenges in net margin, ROE, ROA, and debt management.

Portfolio Pulse from Benzinga Insights

April 18, 2024 | 6:01 pm

BPTH

Bio-Path Holdings, Inc. (NASDAQ:BPTH) announced a registered direct offering and concurrent private placement to institutional investors, selling 375,000 shares at $3.225 each, and issuing warrants for an additional 375,000 shares at $3.10 each. The transactions will increase the outstanding shares from 1,190,306 to 1,565,306, with H.C. Wainwright & Co., LLC as the placement agent. The offering is expected to close on April 19, 2024.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 6:01 pm

F

LULU

RIVN

TSLA

XPEV

Today's session highlighted significant options activity in the Consumer Discretionary sector, with notable movements in stocks like TSLA, XPEV, F, LULU, RIVN, VFC, AMZN, TJX, WING, and AZO. The activity ranged from bullish to bearish sentiments, with trades involving both call and put options across various expiration dates and strike prices. This could indicate potential trading opportunities based on the whales' movements.

Portfolio Pulse from Benzinga Insights

April 18, 2024 | 5:35 pm

ABT

Significant bearish options activity has been detected in Abbott Laboratories (NYSE:ABT), with a notable volume of puts compared to calls among large-scale traders. The options data, showing a mix of bullish and bearish sentiment, suggests a focus on a price range between $75.0 and $125.0 for ABT. Analysts from Citigroup, RBC Capital, and Evercore ISI Group have maintained positive ratings on ABT, with price targets suggesting optimism about the stock's future performance. Despite the bearish options activity, the analysts' outlook and the company's diverse product portfolio may provide a counterbalance.

Portfolio Pulse from Benzinga Insights

April 18, 2024 | 5:32 pm

WINT

Windtree Therapeutics Inc (NASDAQ:WINT) shares dropped 20% to $0.32 after announcing a 1-for-18 reverse stock split effective April 19, 2024, to comply with Nasdaq's minimum bid price requirement. The split aims to increase the market price per share without changing ownership percentages. Windtree Therapeutics has seen an 87.55% decline year to date, underperforming its historical averages. The stock's Relative Strength Index is at 50.46, indicating neutral market conditions.

Portfolio Pulse from Henry Khederian

April 18, 2024 | 5:27 pm

WINT

Windtree Therapeutics' shares are trading lower following the company's approval of a 1-for-18 reverse stock split.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 5:23 pm